OTCPicks.com: OTCPicks.com Stocks to Watch for Monday, August 25th RNVO, OGXI, MEDT, CPRX, FFGO

Mon. August 25, 2008; Posted: 04:23 AM

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

RENOVO HOLDINGS (OTCBB: RNVO | Quote | Chart | News | PowerRating) "Up 200.00% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/RNVO.php

Renovo Holdings does not have significant operations. It intends to acquire or merge with one or more operating businesses. The company, formerly known as Fortis Enterprises, was founded in 2000 and is based in Casselberry, Florida.

RNVO News:

August 22 - Renovo Holdings Updates Shareholders

Renovo Holdings (OTCBB: RNVO | Quote | Chart | News | PowerRating) announced that the company has reached negotiated terms, which have set the framework for significant changes in the company's management and operating structures.

After completion of the transaction, Renovo Holdings will commence operations under the leadership of the new management team. Both the current and incoming management teams are pleased to announce that under the negotiated terms, the parties have agreed that there will be no reverse stock split associated with the transaction.

The company anticipates introducing the new management team and business model in the very near term. The resignation of Stephen W. Carnes, current President of Renovo Holdings, will be accepted and effective concurrently upon the appointment of the company's new management team.

ONCOGENEX PHARMA INCORPORATED (NASDAQ: OGXI | Quote | Chart | News | PowerRating) "Up 63.90% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/OGXI.php

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development.

OGXI News:

August 22 - FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011

OncoGenex Pharmaceuticals (Nasdaq: OGXI | Quote | Chart | News | PowerRating) announced that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer. OGX-011 is currently completing five Phase 2 clinical studies in prostate, lung and breast cancer, and is designed to inhibit the production of a specific protein, clusterin, associated with treatment resistance.

Fast Track designation is granted to products that may provide a significant improvement in the safety or effectiveness of the treatment for a serious or life-threatening disease. Based on this designation, the FDA will take actions as appropriate to expedite the development and review of OGX-011 for approval. These actions include scheduled meetings to obtain FDA input into development plans, the option of submitting a New Drug Application in sections rather than all components simultaneously, and the option of requesting evaluation of studies using surrogate endpoints.

"Obtaining Fast Track designation for custirsen sodium while developing our Phase 3 program for hormone-refractory prostate cancer (HRPC) and in advance of initiating our Phase 3 study is very important and should help us move forward expeditiously on our pathway toward commercialization," said Scott Cormack, chief executive officer of OncoGenex Pharmaceuticals. "We welcome this designation as another example of our ability to rapidly advance our development programs."

The request for Fast Track designation was based on data from Phase 2 studies in HRPC as well as supporting data in non-small cell lung cancer (NSCLC) indicating that OGX-011 treatment can significantly reduce serum clusterin levels and that achieving low serum clusterin levels during treatment is correlated with improved survival. Furthermore, serum clusterin levels during OGX-011 treatment may be predictive of a treatment benefit with OGX-011. In patients with HRPC who had failed first-line docetaxel while on or within six months of first-line docetaxel therapy and received second-line chemotherapy in combination with OGX-011 (Study OGX-011-07), achieving or maintaining low serum clusterin levels correlated with improved survival. Similar results were seen in Study OGX-011-05 in patients with NSCLC who were treated with gemcitabine plus a platinum regimen and OGX-011. Data from the Phase 2 study in HRPC were presented at the 2008 Annual Meeting of the American Society of Clinical Oncology.

MEDIATECHNICS CORPORATION (OTC: MEDT | Quote | Chart | News | PowerRating) "Up 50.00% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/MEDT.php

Mediatechnics Corporation (www.mediatechnicscorporation.com) is the parent company of Mediatechnics Systems Inc., MediaMaster Corporation, The Live Network, Innotech and CRD Technology.

MEDT News:

August 22 - Mediatechnics Announces New Strategic Partnership With Digital Media Applications

Mediatechnics Corporation (OTC: MEDT | Quote | Chart | News | PowerRating) announced a new partnership with Digital Media Applications (DMA), the leading provider of automated DVD authoring solutions and the RocketDVD Professional software application.

Together with Mediatechnics' new DVD production platform, FusionPro and DiscWrite4, DMA's software will enable Mediatechnics to provide their customers with turn-key solutions including, DVD authoring applications with an automated process for capture, disc duplication and distribution of professional DVDs including customized disc labels and DVD case wraps.

Incorporating key support for Mediatechnics' products with RocketDVD will help expand Mediatechnics' market penetration by adding support for two key DMA applications; RocketDVD-Live and RocketDVD-On-Demand.

RocketDVD-Live is an end-to-end automated DVD authoring solution that offers real-time video/audio captures, recording and creation of DVDs during live events. It consists the RocketDVD Professional system, Live feature upgrades and the RocketDVD Duplicator Rack mount Towers, RocketDVD-Live, is completely scalable and can produce a large number of fully authored DVDs within 10 minutes from the conclusion of the event. RocketDVD-Live technology enables the simultaneous receipt of the DVD image file to all DVD Duplicators available on the gigabit Ethernet network. Once receipt of the DVD image file is complete each tower will immediately initiate the writing process on all available drives populated with blank media. Additional DVD runs can be initiated once all drives in the duplicator are repopulated with blank media (actual writing times per 6-drive tower is approximately 6.5 minutes).

Markets: Live Events - Entertainment, Training, Corporate Events, Government, and Education

RocketDVD-On-Demand enables you to fully automate the entire DVD production process from a second application such as a Website, Database or an Asset Management system. By placing a text file with project parameters in a pre-defined hot folder, RocketDVD On Demand will automatically poll the hot folder looking for project files to execute, immediately process the project and send the DVD to the Mediatechnics Fusion system for production. This includes creating a new menu, disc label and custom case wrap for the DVD project. You no longer have to keep DVDs in inventory. With DVD-On-Demand you can create a just-in-time DVD production process while adding the ability for your customers to custom select the video components or assets they want on the DVD.

Markets: Broadcaster, Content Producers, Catalogs, and Education

Digital Media Applications was formed in 2003 to bring to market RocketDVD Professional, a unique and innovative DVD authoring application. The company is made up of industry professionals with backgrounds in DVD Authoring, Video and Network Storage, Video Streaming, Video Conferencing and Video Production. We've used our years of experience and industry knowledge to produce RocketDVDProfessional, the first DVD creation system to incorporate high level DVD Authoring features like; custom menus, custom chaptering, motion menus, variable text fields etc. in a fully automated DVD Authoring and Production solution. Please check out our products page for more information.

CATALYST PHARMACEUTICAL PARTNERS (NASDAQ: CPRX | Quote | Chart | News | PowerRating) "Up 18.40% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/CPRX.php

Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs for the treatment of drug addiction. It is developing CPP-109, a chemical compound gamma-vinyl-GABA based product, which is in Phase II clinical trial for the treatment of addiction to cocaine. The company also intends to develop CPP-109 to treat methamphetamine and other addictions, such as addictions to nicotine, prescription pain medications, alcohol, and marijuana, as well as treatments for obsessive-compulsive disorders, including obesity and compulsive gambling. In addition, it holds a worldwide license from Brookhaven Science Associates to nine patents and four patent applications relating to the use of vigabatrin for a range of indications, including the treatment of various substance addictions. The company was founded in 2002 and is based in Coral Gables, Florida.

CPRX News:

August 21 - Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX | Quote | Chart | News | PowerRating) reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin leads to rapid weight loss and reduced food intake. The data was published online as of August 20, 2008 in the journal Synapse, a prestigious peer-reviewed neuroscience publication.

Catalyst Pharmaceutical Partners is currently evaluating the use of CPP-109, its version of vigabatrin, for the treatment of both cocaine and methamphetamine addiction. Two FDA-approved U.S. Phase II clinical trials are currently ongoing. CPP-109 is an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release.

According to the study published in Synapse, a total of 50 adolescent and adult animals, all genetically bred to be obese, were assigned to either a control group or groups that received vigabatrin at various dose levels and were monitored for up to 40 days. The controls received daily salt water (saline) injections, while those in the study groups received up to 300 milligrams of vigabatrin per day. All animals received injections for two, 7-13 day periods, with breaks in between.

At the end of the 40 day period, all animals receiving vigabatrin weighed significantly less than the control subjects. In fact, those animals that were bred to be obese experienced a loss of up to 19 percent of their total weight, while non-obese animals lost 12 to 20 percent of their total weight following short-term treatment with vigabatrin. Amy DeMarco of Brookhaven led the study working in the laboratory of Brookhaven Lab senior scientist, Stephen Dewey, Ph.D. (Dr. Dewey is the Chairman of Catalyst's Scientific Advisory Board). The Brookhaven National Laboratory press release may be accessed at:

http://www.bnl.gov/bnlweb/pubaf/pr/PR_display.asp?prID=811.

Commenting on today's news, Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceutical Partners, noted, "We are very encouraged by this new animal data, which shows the long-term prospects of using vigabatrin for the treatment of obesity, which is currently at epidemic proportions in the U.S. In addition to development of CPP-109 for treatment of cocaine, methamphetamine and other substance addictions, the compound appears to provide a platform for multiple indications, including as a potential treatment for obsessive compulsive disorders. In fact, as previously reported, we are currently seeking to conduct a Phase II clinical trial later this year evaluating CPP-109 for the treatment of binge eating disorder."

FORTRESS FINANCIAL GROUP INCORPORATED (OTC: FFGO | Quote | Chart | News | PowerRating) "Up 33.33% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/FFGO.php

Fortress Financial Group, Inc. was primarily engaged in the issuing and marketing of prepaid debit card and related payment solution activities. Through the closure of the Trinity Mercantile Finance Group and the Mortgage Bank acquisitions; Fortress Financial Group, Inc. is now expediting its plans to become a broadly based Consumer Finance Group. The "Mortgage and Consumer Lending Divisions" will comprise the vast majority of the Group's earnings in the immediate to medium term. The Company is utilizing is substantial Balance Sheet of circa US$100 million comprised of quoted and unquoted Gold Mining & Exploration stocks (this is after the payment of the Extraordinary Dividend of US$400 million to stockholders); to aggressively fund a large number of acquisitions in the consumer financial services sector; initially focused in the Mortgage Lending and Banking sectors.

FFGO News:

August 22 - Fortress Financial Group, Inc. Receives Substantial Bid for Gold Assets

Company Confirms That It Has Received a 30% Higher Bid for Its Gold Assets

Fortress Financial Group, Inc. (OTC: FFGO | Quote | Chart | News | PowerRating) confirms that it has received a very substantially higher bid for its "Bouse" and its "South Copperstone" Gold assets.

The Company will announce full details prior to the market open on Monday, August 25, 2008.

This will not delay any payments of dividends, and should this bid be accepted it will increase the dividend payment by as much as 30%.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer:Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for CPRX click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index